InflaRx (IFRX) Return on Capital Employed Growth (3y) (2020 - 2026)
InflaRx (IFRX) Return on Capital Employed Growth (3y) (2020 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -356.00 |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -516.00 |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -4,078.00 |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 4,967.00 |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 5,777.00 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -9,445.00 |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 109.00 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 513.00 |
| 10 | InflaRx | 140.30 Mn | -43.96 Mn | 2.74 Bn | 3,784.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3,427.00 |
| Dec 31, 2025 | 3,949.00 |
| Sep 30, 2025 | 5,073.00 |
| Jun 30, 2025 | 4,348.00 |
| Mar 31, 2025 | 5,386.00 |
| Dec 31, 2024 | 4,336.00 |
| Sep 30, 2024 | -7,050.00 |
| Jun 30, 2024 | 474.10 Mn |
| Mar 31, 2024 | 569.41 Mn |
| Dec 31, 2023 | 750.70 Mn |
| Sep 30, 2023 | -3.89 Bn |
| Jun 30, 2023 | -2.82 Bn |
| Mar 31, 2023 | -2.56 Bn |
| Dec 31, 2022 | -2.30 Bn |
| Sep 30, 2022 | 1.25 Bn |
| Jun 30, 2022 | -3,423.00 |
| Mar 31, 2022 | -5,314.00 |
| Dec 31, 2021 | -4,376.00 |
| Sep 30, 2021 | 1.83 Bn |
| Jun 30, 2021 | 1.60 Bn |